Galantamine Hydrobromide

CHEMBL1555 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
368.3 g/mol
LogP
Phase
4

This hydrobromide salt form of galantamine is used to manage the cognitive and functional symptoms of mild to moderate Alzheimer's disease by boosting acetylcholine neurotransmission in the brain. It is taken orally and is one of the standard acetylcholinesterase inhibitors used in dementia care.

Peso molecular

368,3000 g/mol

TPSA

41,90 Ų

Áreas terapéuticas

Mecanismo de acción

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Br.COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2

InChI

InChI=1S/C17H21NO3.BrH/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17;/h3-6,12,14,19H,7-10H2,1-2H3;1H/t12-,14-,17-;/m0./s1

Molecular Formula

C17H22BrNO3

HBD / HBA

2 / 4

Enlaces Rotables

1

Átomos Pesados

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

This hydrobromide salt form of galantamine is used to manage the cognitive and functional symptoms of mild to moderate Alzheimer's disease by boosting acetylcholine neurotransmission in the brain. It is taken orally and is one of the standard acetylcholinesterase inhibitors used in dementia care.

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Yes, Galantamine Hydrobromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1555. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 121587. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.